Company Encyclopedia
View More
name
PolyPid
PYPD.US
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc.
4.513 T
PYPD.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Polypid Announces Positive FDA Pre-NDA Meeting Minutes

    PolyPid Ltd :POLYPID ANNOUNCES POSITIVE FDA PRE-NDA MEETING MINUTES FOR D-PLEX₁₀₀ SUPPORTING NDA SUBMISSIONPOLYPID LTD - FDA AGREED TO A ROLLING NDA REVIEW, ALLOWING POLYPID TO SUBMIT FIRST COMPLETED SECTIONS IN EARLY 2026

    Reuters·
    US
    PYPD
    -0.51%
    Reuters·
    US
    PYPD
    -0.51%

    Roth MKM Remains a Buy on PolyPid (PYPD)

    Roth MKM's Boobalan Pachaiyappan maintains a Buy rating on PolyPid with a $9.00 price target. Despite Pachaiyappan's average return of -10.0% and a 34.31% success rate, the general analyst consensus is a Strong Buy for PolyPid, with an average price target of $11.00.

    Tip Ranks·
    US
    PYPD
    -0.51%
    Tip Ranks·
    US
    PYPD
    -0.51%

    PolyPid Ltd. Advances Towards Key Milestones in 2025

    PolyPid Ltd. (PYPD) has reported its Q3 earnings, highlighting progress in its regulatory and commercial strategies. The company plans to submit a New Drug Application for D-PLEX 100 in early 2026, following a successful Phase 3 trial. PolyPid recorded a net loss of $7.5 million for Q3 2025, an improvement from $7.8 million in Q3 2024, with a cash position of $18.8 million. The company has completed a successful inspection by the Israeli Ministry of Health and conducted U.S. market research to support D-PLEX 100's value proposition, positioning itself for future growth in the biopharma sector.

    Tip Ranks·
    US
    PYPD
    -0.51%
    Tip Ranks·
    US
    PYPD
    -0.51%

    PolyPid Ltd. Earnings Call: Progress and Potential

    PolyPid Ltd. held its Q3 earnings call, highlighting significant progress towards regulatory approval for its product DPLEX 100. The company reported a reduced net loss of $7.5 million and increased cash reserves to $18.8 million. Positive Phase III trial results showed a 58% reduction in surgical site infections, generating strong interest from medical professionals. Despite rising administrative and marketing expenses, the overall sentiment remains optimistic, with plans for a pre-NDA meeting with the FDA and a European Marketing Authorization Application. The company is well-positioned for future growth and market expansion.

    Tip Ranks·
    US
    PYPD
    -0.51%
    Tip Ranks·
    US
    PYPD
    -0.51%

    PolyPid’s Promising Future: Buy Rating Backed by D-PLEX100 Progress and Expanding Drug Delivery Pipeline

    Analyst Brandon Folkes of H.C. Wainwright has reiterated a Buy rating on PolyPid, maintaining a price target of $13.00. This rating is supported by the promising progress of D-PLEX100, which is set for NDA submission in early 2026 after positive Phase 3 trial results. The product shows significant efficacy in reducing surgical site infections. Additionally, PolyPid is expanding its drug delivery technology, with potential new products targeting obesity and diabetes. The company’s strong operational performance and favorable market cap of $60M enhance its risk-reward profile.

    Tip Ranks·
    US
    PYPD
    -0.51%
    Tip Ranks·
    US
    PYPD
    -0.51%
    © 2025 Longbridge｜Disclaimer